Page 233 - Programme book for The International Liver Congress 2015, EASL ILC 2015

P0654 LONG-TERM SUSTAINED SUPPRESSION OF VIRAL ePOSTERS
P0655 REPLICATION IS ASSOCIATED WITH LOW HBSAG LEVELS
IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED
P0656 WITH NUCLEOS(T)IDE ANALOGUES (NUCS)
P0657 Emilio Suárez*, Martín Prieto, Carmen A. Navascués, Elena Hoyas,
P0658 Vanessa Hontagas, María Luisa González-Gieguez, Blanca Figueruela,
María García-Eliz, Manuel Rodríguez, Spain

LAMIVUDINE PROPHYLAXIS PREVENTS HEPATITIS
B REACTIVATION IN HBSAG-NEGATIVE/ANTI-HBC-
POSITIVE PATIENTS UNDERGOING RITUXIMAB-BASED
CHEMOTHERAPY FOR NON–HODGKIN’S B CELL
LYMPHOMA
Mauro Viganò*, Glenda Grossi, Edoardo Borsotti, Mattia Cappelletti,
Maria Goldaniga, Lucia Farina, Mariagrazia Rumi, Paolo Corradini,
Luca Baldini, Massimo Colombo, Pietro Lampertico, Italy

ADD ON PEGINTERFERON TO ADEFOVIR ENHANCES
HBSAG LOSS IN INACTIVE HBV CARRIERS
Michelle Martinot Peignoux, Feryel Mouri, Nathalie Boyer,
Corrine Castelnau, Michèle Pouteau, Nathalie Giuly, Tarik Asselah,
Patrick Marcellin*, France

ADDING TENOFOVIR TO PEGYLATED INTERFERON
ENHANCE END OF TREATMENT HBSAG LOSS IN HBEAG
NEGATIVE CHRONIC HEPATITIS B PATIENTS
Patrick Marcellin*, Michelle Martinot Peignoux, Rami Moucari,
Martine Lapalus, Corrine Castelnau, Feryel Mouri, Michèle Pouteau,
Nathalie Giuliy, Nathalie Boyer, Tarik Asselah, France

A NEW PROGNOSTIC MODEL FOR 1-YEAR MORTALITY IN
PATIENTS WITH DECOMPENSATED HEPATITIS B VIRUS-
RELATED LIVER CIRRHOSIS RECEIVING ANTIVIRAL
TREATMENT
Tae Hyung Kim*, Soon Ho Um, Dae Hoe Gu, Seok Bae Yoon,
Tae Jung Yun, Sun Young Yim, Jin Young Jung,Yeon Seok Seo,
Hyung Joon Yim, Bora Keum,Yoon Tae Jeen, Hong Sik Lee,
Hoon Jai Chun, Chang Duck Kim, Ho Sang Ryu, South Korea

Vienna, Austria • April 22–26, 2015 233